Knee Replacement Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Knee replacement surgery — total knee arthroplasty (TKA) — involves the systematic resurfacing of the distal femur, proximal tibia, and optionally the patella using metal alloy and polyethylene implant components. The procedure is performed under regional or general anaesthesia, typically lasts 60–120 minutes, and has undergone substantial evolution in technique over the past two decades. Contemporary best practice is guided by Enhanced Recovery After Surgery (ERAS) principles that prioritise shorter hospital stays, earlier mobilisation, reduced opioid use, and improved patient experience without compromising safety or implant outcomes.

More than 800,000 TKAs are performed annually in the United States and over 100,000 in the United Kingdom. The UK National Joint Registry (NJR) reports 15-year implant survival exceeding 90% for primary TKA, confirming the procedure's durability. Pre-operative preparation, meticulous surgical technique, and structured rehabilitation are equally important determinants of success. Understanding the stages of surgery helps patients engage actively with their care team and set realistic expectations.

This guide focuses on the intra-operative and peri-operative aspects of knee replacement surgery — from anaesthetic choice through surgical exposure, bone preparation, blood management, and the evidence base behind each decision. For a patient-focused overview including recovery timelines and activity advice, see our Knee Replacement patient guide.

Knee replacement surgery is indicated for end-stage arthritis of the knee — most commonly primary osteoarthritis, rheumatoid arthritis, or post-traumatic arthritis — that has failed a structured course of conservative management (physiotherapy, NSAIDs, intra-articular injections) for at least three to six months.

Pre-operative optimisation (prehabilitation): Modern ERAS programmes begin weeks before surgery. Pre-operative physiotherapy ('prehabilitation') strengthening the quadriceps and hamstrings correlates with faster post-operative recovery. Nutritional screening identifies patients with protein deficiency or anaemia who benefit from iron supplementation or dietary intervention. Pre-operative haemoglobin should ideally exceed 120 g/L in women and 130 g/L in men to minimise transfusion need. Patient Blood Management (PBM) protocols initiated 4–6 weeks pre-operatively treat iron deficiency anaemia before the surgical blood loss occurs.

Medical optimisation: Glycaemic control (HbA1c <7.5–8%) is recommended to reduce infection risk. Smoking cessation (ideally 4–8 weeks pre-operatively) significantly reduces wound complications and chest infection. Immunosuppressive medications (methotrexate, biologics in RA) require specific peri-operative management in liaison with rheumatology. MRSA screening and decolonisation (nasal mupirocin, chlorhexidine body wash) are standard in many high-volume centres. Antibiotic prophylaxis (typically cefazolin or teicoplanin IV) is administered 30–60 minutes before skin incision.

Surgical consent: Informed consent covers the expected benefits, risks (infection, DVT/PE, nerve injury, implant failure), alternatives, and realistic recovery timeline. Consent must be unhurried and documented appropriately.

Anaesthetic choice is a shared decision between patient, surgeon, and anaesthetist, guided by patient preference, comorbidities, and ERAS evidence.

Spinal (intrathecal) anaesthesia: Preferred in contemporary ERAS protocols for most TKA patients. Spinal anaesthesia with isobaric or hyperbaric bupivacaine provides excellent surgical conditions, avoids the haemodynamic instability and airway risks of general anaesthesia, reduces post-operative nausea and vomiting, and is associated with lower VTE rates. A 2019 Cochrane review found spinal anaesthesia associated with reduced blood loss and transfusion requirement versus general anaesthesia for TKA. Addition of intrathecal opioids (e.g., morphine 100 mcg) extends post-operative analgesia for 12–18 hours.

General anaesthesia (GA): Preferred or required in patients with coagulopathy, prior lumbar spine surgery, patient refusal of regional techniques, or anaesthetic assessment determining higher risk with spinal. Total intravenous anaesthesia (TIVA) with propofol and remifentanil reduces post-operative nausea compared to inhalational agents.

Peripheral nerve blocks: The adductor canal block (ACB) has largely replaced the femoral nerve block (FNB) for TKA analgesia, as it provides equivalent pain control while preserving quadriceps strength, enabling earlier mobilisation and reducing fall risk. The ACB targets the saphenous nerve in the adductor canal for sensory-only analgesia. Infiltration of local anaesthetic around the knee (local infiltration analgesia, LIA) using ropivacaine ± ketorolac ± adrenaline at the time of surgery provides effective supplemental pain control.

Multimodal opioid-sparing analgesia: ERAS protocols use scheduled paracetamol, NSAIDs or COX-2 inhibitors, gabapentinoids (pregabalin or gabapentin), dexamethasone, and regional blocks as a package to minimise opioid use, thereby reducing nausea, constipation, urinary retention, and respiratory depression.

The surgical procedure proceeds through several defined stages, each with evidence-based variations in technique.

Tourniquet use: A pneumatic tourniquet (250–350 mmHg) applied to the proximal thigh has traditionally been used to provide a bloodless operative field, facilitating cement interdigitation. However, the evidence base for routine tourniquet use has weakened considerably. Randomised trials show tourniquet use increases post-operative pain, quadriceps inhibition, and risk of VTE while not clearly reducing overall blood loss when tranexamic acid (TXA) is used. Many high-volume surgeons now perform TKA without tourniquet or use it only during cementation.

Surgical approaches: Three exposures are commonly used:
— Medial parapatellar approach: The classical and most widely used approach; splits the quadriceps tendon and medial retinaculum, providing excellent exposure of all three compartments. Suitable for complex cases, revision surgery, and standard primary TKA.
— Midvastus approach: Splits the vastus medialis muscle fibres obliquely rather than the quadriceps tendon, preserving the extensor mechanism continuity. Associated with earlier straight leg raise and shorter hospital stay in some studies; technically more demanding in obese patients or with stiff joints.
— Subvastus approach: Entirely avoids the quadriceps tendon; most tissue-sparing but limited by restricted exposure in muscular or obese patients. Best suited to slim patients undergoing elective primary TKA.

Bone cuts and alignment: Distal femoral and proximal tibial cuts are made using intramedullary (IM) or extramedullary (EM) guide systems, or computer navigation / robotic guidance. IM femoral guides reference the intramedullary canal for coronal alignment. Target mechanical alignment (neutral mechanical axis) has been the standard; kinematic alignment (which recreates the patient's native joint line and ligament tension) is gaining interest with growing evidence of improved patient satisfaction in selected series.

Patellar resurfacing: Whether to resurface the patella with a polyethylene button remains one of the most debated topics in TKA. Meta-analyses and the TOPKAT trial show no clear functional outcome difference between resurfaced and non-resurfaced patella in primary TKA, though non-resurfaced knees have a higher rate of secondary patella resurfacing (approximately 7%). Many UK and Australian surgeons routinely resurface; US practice is more variable.

Blood management — Tranexamic acid (TXA): TXA is a synthetic antifibrinolytic that blocks plasminogen activation, significantly reducing surgical blood loss. Intravenous TXA (15–20 mg/kg at induction) reduces mean blood loss by 300–500 mL and transfusion requirement by 30–50% without a meaningful increase in VTE risk in standard-risk patients. Topical intra-articular TXA is an alternative in patients with contraindications to systemic TXA. TXA use has made surgical drains largely redundant; most ERAS programmes have abandoned routine drain placement.

The integration of ERAS principles has transformed TKA from a procedure requiring 7–10 days of hospitalisation to one where discharge at 2–3 days — or same-day discharge in carefully selected patients — is routine. Evidence-based benefits include:

• Reduced opioid consumption: Multimodal analgesia and regional nerve blocks reduce in-hospital opioid requirements by 30–50%, decreasing nausea, ileus, urinary retention, and respiratory depression.
• Earlier mobilisation: Day-of-surgery or Day-1 mobilisation with physiotherapy reduces VTE risk, improves early range of motion, and shortens hospital stay without increasing readmission or complication rates.
• Lower transfusion rates: TXA use has virtually eliminated allogeneic blood transfusion needs in standard-risk TKA patients, reducing associated risks (transfusion reactions, infection, prolonged stay).
• Shorter hospital stay: ERAS-driven discharge criteria (adequate pain control on oral analgesics, ability to mobilise with aids, independent stair negotiation) allow 2–3-day discharge in most elective primary TKA patients.
• Excellent long-term durability: NJR data confirm 15-year implant survival exceeding 90%, with best-performing implant systems approaching 95% at 20 years.

Outpatient (day-case) TKA is performed at selected high-volume centres in the US, UK, and Australia for ASA I–II patients under 70 with strong home support, demonstrating comparable safety to inpatient TKA in appropriately selected patients.

Despite excellent overall outcomes, TKA carries recognised surgical and anaesthetic risks that must be communicated during consent.

Venous thromboembolism (VTE): Deep vein thrombosis (DVT) affects up to 2–4% of TKA patients on modern prophylaxis protocols; pulmonary embolism (PE) in 0.3–0.5%. NICE NG89 recommends 10–14 days of chemical thromboprophylaxis (LMWH or DOAC such as rivaroxaban) with mechanical compression and early mobilisation. Extended prophylaxis to 35 days is recommended in patients with additional risk factors.

Periprosthetic joint infection (PJI): Affects 1–2% of primary TKA cases. Early PJI (<4 weeks) may be treated with irrigation, debridement, and implant retention (DAIR procedure); late or chronic PJI typically requires two-stage revision (implant removal, antibiotic spacer, reimplantation 6–12 weeks later). Pre-operative MRSA screening and decolonisation reduce gram-positive infection risk.

Intra-operative fracture: Tibial or femoral fractures can occur during bone cutting, particularly with osteoporotic bone. Incidence is approximately 0.5%; intra-operative fixation with screws or stems may be required.

Nerve injury: Common peroneal nerve palsy occurs in 0.3–1% of cases, more frequent in severe valgus deformity, significant haematoma, or prolonged tourniquet use. Most resolve spontaneously within 6–12 months; persistent deficit may require orthotics.

Wound complications: Superficial wound infection, delayed healing, or haematoma formation affects 1–3% of patients. Risk is elevated with obesity, diabetes, immunosuppression, and prolonged operative time.

Anaesthetic risks: Spinal anaesthesia complications include post-dural puncture headache (<1%), spinal haematoma (<0.01%), and transient neurological symptoms. General anaesthesia carries risks of aspiration, awareness under anaesthesia, and cardiovascular events, particularly in older patients with comorbidities.

Structured post-operative recovery is as important as the surgery itself. Discharge readiness is assessed against standardised functional criteria rather than fixed time points.

Discharge criteria (ERAS standard): Adequate pain control on oral analgesics (VAS <4/10 at rest); ability to mobilise safely with walking aids (minimum 20 metres); independent stair negotiation with a banister; wound integrity with no signs of early infection; adequate oral intake; completed VTE prophylaxis education. Most patients meet these criteria within 2–3 days; medically fit patients with strong home support may meet them within 23 hours.

Day 0–14 (Acute recovery): Ice packs (15–20 minutes, 3–4 times daily) and limb elevation reduce swelling. Thromboprophylaxis is taken as prescribed (LMWH injection or oral DOAC). Wound review at 10–14 days; staples or clips removed. Physiotherapy appointments begin within days of discharge — focus on range of motion, active quadriceps exercises, and gait training. Avoiding prolonged sitting (>60 minutes without moving the knee) reduces stiffness.

Weeks 2–6: Progressive increase in walking distance; stair climbing proficiency; discontinuation of walking frame in favour of a single crutch or walking stick. Most patients no longer require regular analgesia by 4–6 weeks. Driving (left knee only for automatic, or right knee for manual/automatic) is typically approved at 4–6 weeks.

Months 3–12: Three months marks the milestone at which most patients walk without aids and perform most activities of daily living. Final functional gains, particularly in stiffness and strength, continue accruing for 9–12 months. Return to workplace (sedentary) is typically at 6–8 weeks; manual work at 3–4 months.

Long-term follow-up: Annual clinical and radiographic review for two years; five-yearly thereafter. Patients should report any unexplained pain, swelling, or functional decline promptly — these may indicate early implant complications.

The cost of knee replacement surgery varies substantially based on healthcare system, institutional volume, implant choice, and length of stay.

United Kingdom (NHS): NHS tariff for primary TKA is approximately GBP 6,500–8,000 per episode including implant, hospital stay, and physiotherapy. Private patients in the UK pay GBP 10,000–18,000 depending on hospital and surgeon.

United States: Total 90-day episode cost averages USD 18,000–30,000 under bundled payment models. Outpatient TKA reduces costs significantly — facility fees in outpatient ambulatory surgery centres average 30–40% less than inpatient hospital settings.

Medical tourism destinations: India: USD 4,000–7,000 (bilateral USD 7,000–12,000); Thailand: USD 8,000–14,000; Malaysia: USD 7,000–12,000; Turkey: USD 6,000–10,000; Mexico: USD 8,000–15,000. These prices typically include surgeon fee, implant, hospital stay, and basic physiotherapy but exclude travel, accommodation, and post-repatriation care.

Key cost drivers: Implant system (standard vs. premium vs. robotic-compatible); use of robotic-assisted technology (adds approximately USD 1,500–3,000 per case); bilateral TKA (higher per-procedure cost but single anaesthetic and hospital admission); post-acute rehabilitation setting (inpatient rehab adds USD 3,000–8,000 in US but outpatient physiotherapy produces equivalent outcomes); revision surgery (two to four times the primary cost).

Insurance considerations: Most health insurance policies cover TKA when clinical criteria are met. Pre-authorisation typically requires evidence of failure of conservative management and radiographic severity documentation.

Surgery should follow a documented trial of non-operative treatment. Alternatives to TKA include:

Structured physiotherapy: Neuromuscular exercise programmes (GLAD, NEMEX) with pain education and activity modification are first-line treatment for knee OA of any severity. Weight loss of 5–10% body weight produces clinically significant pain reduction. Exercise programmes should be continued alongside other treatments.

Pharmacotherapy: Topical diclofenac is preferred over oral NSAIDs in elderly patients due to lower systemic risk. Oral NSAIDs and COX-2 inhibitors provide effective short-term pain control. Duloxetine (60–120 mg daily) is licensed for chronic musculoskeletal pain and has an evidence base in knee OA. Long-term opioid use is not recommended due to lack of efficacy and significant harm.

Intra-articular therapies: Corticosteroid injections (triamcinolone, methylprednisolone) reduce inflammation for 4–8 weeks; useful for acute flares before surgery. Hyaluronic acid injections have variable evidence and are not routinely recommended by NICE for knee OA. Platelet-rich plasma (PRP) has growing evidence in mild-to-moderate OA but limited data in severe disease.

Bracing and orthotics: Valgus-producing knee braces reduce medial compartment load in isolated medial OA; benefit is modest and depends on patient compliance and body habitus. Lateral heel wedge insoles have not shown consistent benefit in RCTs.

Surgical alternatives: High tibial osteotomy (HTO) corrects varus alignment and offloads the medial compartment, delaying TKA by 10–15 years in younger (<60 years), active, varus-malaligned patients with isolated medial OA. Unicompartmental knee arthroplasty (UKA) is indicated for isolated compartmental OA meeting strict selection criteria. Arthroscopic debridement is not recommended for knee OA based on high-quality RCT evidence.